August 12, 2020 Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020 HOUSTON, Aug. 12, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended June 30, 2020 and provided a business update. Management Discussion Walter Klemp, Chairman and CEO of Moleculin, stated, "Despite the difficult backdrop resulting from the global pandemic, we made tremendous progress across all three of our core technologies, particularly in our infectious disease...
|
